Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.
The Syapse Network enables health systems and their providers to learn from real-world treatment and outcomes data shared by leading institutions. Providers can view which treatments provided the best outcomes for clinically and molecularly similar patients at the point of care with a large pool of real-world data generated by a national network of leading institutions. Insights are accessible to Syapse health system partners through Syapse Oncology.
Impact of Partnership with Pfizer
“Pfizer is on the forefront of utilizing real-world data to improve the lives of patients worldwide and we are pleased to work with them to unlock evidence and insights that can help improve patient care and accelerate the availability of new treatments,” said Ken Tarkoff, CEO of Syapse. “To realize the potential of precision medicine all of the stakeholders in the healthcare ecosystem need to work together. At Syapse, we are proud of the collaborations we are facilitating between life science companies and health systems and we are committed to translating this work into solutions that help providers deliver consistent, cost-effective, patient-centered cancer care.”